Boston University
Repurposing Rho-associated kinase (ROCK) inhibitors for the treatment of Alzheimer’s disease: it’s time to ROCK and Rho
Abstract
dc:description.abstractAlzheimer’s disease (AD) is a neurodegenerative disease that has no cure. AD is primarily characterized by extracellular amyloid-beta (Aβ)-containing neuritic plaques and intracellular phosphorylated tau-containing neurofibrillary tangles. There are medications available for AD patients. Examples include acetylcholinesterase inhibitors (AChE-I), N-methyl-D-aspartate receptor antagonists (NMDAR-A), and anti-amyloid therapies (AAT). However, the AChE-I and NMDAR antagonists only treat the symptoms of AD. AAT, while disease-modifying, comes with severe side effects known as amyloid-related imaging abnormalities (ARIAs) with microhemorrhage and edema. Therefore, there is a need for AD treatments that are safe and target the symptoms and pathology of AD. Rho-associated kinase (ROCK) is a ubiquitously expressed serine-threonine kinase with two different isoforms: ROCK 1 and ROCK 2. Both are highly homologous, but ROCK2 is more abundant in the brain and skeletal muscles. ROCK plays a vital role in cytoskeletal regulation, cell migration, cell proliferation, and cell survivability. Importantly, the dysregulation of ROCK activity has been implicated in the onset and the progression of AD pathology. Both isoforms are upregulated in the brains of AD patients. ROCK promotes amyloidogenic processing of APP by phosphorylating amyloid precursor protein (APP) and beta-secretase (BACE), and ROCK promotes the hyperphosphorylation of tau via the inhibition of AKT. Pharmacological inhibition of ROCK has shown promising results, as it reduces Aβ load and levels of total and phosphorylated tau (ptau) in the brains of AD mouse models. Here we show that ROCK inhibitor netarsudil which is FDA-approved and commercially available in the United States, can penetrate the blood-brain barrier (BBB) and exhibit prolonged retention in the brain relative to the systemic circulation. Additionally, analysis of brain tissue from mice exposed to netarsudil demonstrated that it decreased levels of total tau and/or ptau in wild-type mice. Proteomic profiling using mass spectrometry revealed that netarsudil enriched neuroprotective proteins, such as metallothionein 1 and 2, and suppressed neurodegenerative proteins such as Serpina3m. To further demonstrate the potential efficacy of netarsudil, we conducted a retrospective study to establish a beneficial association between netarsudil prescriptions and the onset of AD in the veteran population. We found that patients prescribed netarsudil tended to have a lower hazard ratio for developing AD, relative to unprescribed patients. Similarly, Kaplan-Meier survival analysis visually demonstrated that patients prescribed netarsudil had a delayed onset of AD. Thus, netarsudil shows potential for treating AD, supporting future efficacy studies in AD mouse models, specifically in ameliorating the Aβ and tau pathology and cognitive impairment
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Pharmacology
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Cambi, Xavier Alexander
- Advisor dc:contributor.advisor
-
- Xia, Weiming
- ORCID dc:identifier.orcid
Subjects
dc:subject × 8Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53554